Literature DB >> 10996582

Drug-induced hyperkalemia: old culprits and new offenders.

M A Perazella1.   

Abstract

Prescribed medications, over-the-counter drugs, and nutritional supplements are used by many patients. Although most of these products are well tolerated, drug-induced hyperkalemia may develop in patients with underlying renal impairment or other abnormalities in potassium handling. Drug-induced hyperkalemia most often occurs from impaired renal potassium excretion. However, disturbed cellular uptake of a potassium load as well as excessive ingestion or infusion of potassium-containing substances may also occur. Physicians must be aware of medications that can precipitate hyperkalemia, how these drugs induce alterations in potassium homeostasis, and the patient characteristics that increase the risk of hyperkalemia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10996582     DOI: 10.1016/s0002-9343(00)00496-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  46 in total

1.  Danger of salt substitutes that contain potassium in patients with renal failure.

Authors:  C J Doorenbos; C G Vermeij
Journal:  BMJ       Date:  2003-01-04

2.  Trimethoprim-induced hyperkalaemia -- lessons in data mining.

Authors:  Manfred Hauben
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

3.  Hyperkalaemia associated with hydroxyurea in a patient with polycythaemia vera.

Authors:  Srecko Marusic; Nives Gojo-Tomic; Vesna Bacic-Vrca; Velimir Bozikov
Journal:  Eur J Clin Pharmacol       Date:  2010-12-14       Impact factor: 2.953

4.  Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals.

Authors:  Elena Ramírez; Tomás Rossignoli; Armando J Campos; Raúl Muñoz; Claudia Zegarra; Hoi Tong; Nicolás Medrano; Alberto M Borobia; Antonio J Carcas; Jesús Frías
Journal:  Eur J Clin Pharmacol       Date:  2012-05-31       Impact factor: 2.953

5.  Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.

Authors:  Pantelis A Sarafidis; Rochelle Blacklock; Eleri Wood; Adam Rumjon; Shanique Simmonds; Jessica Fletcher-Rogers; Rachel Ariyanayagam; Aziza Al-Yassin; Claire Sharpe; Katie Vinen
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-17       Impact factor: 8.237

6.  Aldosterone receptor antagonists: effective but often forgotten.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Circulation       Date:  2010-02-23       Impact factor: 29.690

Review 7.  Pathogenesis, diagnosis and management of hyperkalemia.

Authors:  Anja Lehnhardt; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2010-12-22       Impact factor: 3.714

8.  Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients.

Authors:  Jörg Indermitte; Sabine Burkolter; Jürgen Drewe; Stephan Krähenbühl; Kurt E Hersberger
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Long-term continuous administration of a hydro-ethanolic extract of Synedrella nodiflora (L) Gaertn in male Sprague-Dawley rats: biochemical, haematological and histopathological changes.

Authors:  Patrick Amoateng; Samuel Adjei; Dorcas Osei-Safo; Believe Ahedor; Seidu A Mahmood; Benoit B N'guessan; Isaac J Asiedu-Gyekye; Alexander K Nyarko
Journal:  Ghana Med J       Date:  2016-09

10.  Patient-reported and actionable safety events in CKD.

Authors:  Jennifer S Ginsberg; Min Zhan; Clarissa J Diamantidis; Corinne Woods; Jingjing Chen; Jeffrey C Fink
Journal:  J Am Soc Nephrol       Date:  2014-02-20       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.